Intrexon
Corp. (NYSE: XON) and Ziopharm Oncology Inc. (Nasdaq: ZIOP) entered an
exclusive
licensing agreement with the University of Texas MD Anderson Cancer
Center to develop non-viral adoptive cellular cancer immunotherapies.
Shares of Intrexon leaped $9.50 to $37.87 while Ziopharm stock surged
$3.11 to $8.85.
Intrexon and Ziopharm enter exclusive license agreement
January 14, 2015 at 12:41 PM EST